NCT06227377 - QTX3034 in Patients With KRAS G12D Mutation | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions

Solid Tumors

Interventions

DRUG

QTX3034

QTX3034 will be administered at protocol defined dose

COMBINATION_PRODUCT

Cetuximab

Cetuximab will be administered at protocol defined dose.

Trial Locations (14)

10016

RECRUITING

NYU Langone Health, New York

10461

RECRUITING

Montefiore Medical Center, The Bronx

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

27710

RECRUITING

Duke University, Durham

33612

RECRUITING

Moffitt Cancer Center, Tampa

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

SCRI- Nashville, Nashville

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

77030

RECRUITING

MD Anderson, Houston

78229

RECRUITING

START San Antonio, LLC, San Antonio

80218

RECRUITING

Sarah Cannon Research Institute (SCRI), Denver

84112

RECRUITING

University of Utah, Huntsman Cancer Center, Salt Lake City

90095

RECRUITING

UCLA Hematology/Oncology, Los Angeles

06511

RECRUITING

Yale Cancer Center, New Haven